Immunology

Immunology

  • Biosimilar payer communications in dermatology, gastroenterology and immunology
  • Development of a payer value deck in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
  • Payer value slides for a varicella vaccine
  • Payer value slides for immunology biosimilars
  • Payer value slide deck in muscle relaxation management
  • Payer value deck for an MMR and varicella vaccine
  • Payer focused value communication on rheumatoid arthritis
  • Payer material development for vaccines in hepatitis A, rotavirus gastroenteritis (RVGE), shingles, varicella and pneumococcal disease
  • Payer evidence dossier for a new psoriasis treatment
  • Payer value proposition in rheumatoid arthritis
  • Communications package in hereditary angioedema
  • Patient support programme, payer communication tool and briefing pack in immunology
  • Frequently asked questions deck in juvenile idiopathic arthritis
  • Frequently asked questions to support the introduction of a new biosimilar in immunology
  • Frequently asked questions for biosimilar policy in immunology
  • Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
  • Workshop and FAQ development in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
  • Literature and content searches for global value dossiers in dermatology and immunology
  • Structured literature review for allergy immunotherapy, including medication adherence compared to other treatments
  • Strategic literature review and gap analysis in systemic lupus erythematosus and lupus nephritis
  • Communication of a literature review on systemic lupus erythematosus and lupus nephritis
  • Literature review of unmet need in rheumatoid arthritis
  • Literature review and update to budget impact model in an immunology biosimilar
  • Targeted literature review in psoriatic arthritis patients with concomitant moderate to severe psoriasis
  • Health economics training and model training in immunology
  • Interactive model in immunology
  • Economic workshop in immunology
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Total Brand FAQ deck and Total Brand Workshop in rheumatoid arthritis, prostate-specific antigen (PsA), psoriasis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis
  • Updates to a US budget impact model for an immunology biosimilar
  • AMCP dossier, budget impact model and global value dossier development in immunology
  • Update for a core value dossier in uveitis
  • Early global value dossiers for a new monoclonal antibody in Crohn’s disease and psoriasis
  • Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease, osteoarthritis, psoriasis and rheumatoid arthritis
  • Update to an AMCP dossier for an immunology biosimilar
  • Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar
  • Two competitor review decks in psoriatic arthritis and ankylosing spondylitis
  • Two competitor reviews in psoriatic arthritis
  • Competitor value story in rheumatoid arthritis
  • Competitor value story in psoriatic arthritis
  • Competitor review of two JAK inhibitors in rheumatoid arthritis
  • Cross-therapy area value proposition alignment in immunology
  • Originator vs. biosimilar value proposition update in immunology
  • Regulatory support on SMC questions on psoriatic arthritis work
  • Product value insight evaluation and strategy in atopic dermatitis
  • Core value dossier on psoriatic arthritis
  • Identification of PRO measures suitable for implementation in phase III oncology and immunotherapy trials
  • Analysis of a PRO and resource utilization in systemic lupus erythematosus
  • Critical review of PRO instruments in systemic lupus erythematosus and fatigue and pain in rheumatic disease
  • Review of PROs in systemic sclerosis/scleroderma
  • Development of posters on the analysis of a PRO and resource utilization in systemic lupus erythematosus
  • Patient focused outcomes in amyloidosis: Exit interviews to capture the patient experience of systemic amyloidosis, treatment and clinical trial participation
  • Translation and linguistic validation of clinician assessments in ACEI-Angioedema
  • Communications on clinician assessments in ACEI-Angioedema
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)
  • Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
  • Regulatory support for the validation of a questionnaire for influenza vaccination
  • Demonstrating the value of antibiotic resistance testing software
  • Modification of the Eosinophilic Esophagitis Activity Index (EEsAI)